Source: https://patents.justia.com/patent/9234223
Timestamp: 2020-04-04 13:17:55
Document Index: 305743890

Matched Legal Cases: ['§119', 'Application No. 61', 'Application No. 20050112731', 'Application No. 20050009162', 'Application No. 2009298136', 'Application No. 20100047879', 'Application No. 20050069994', 'Application No. 20050112731', 'Application No. 20050112731', 'Application No. 20050112731', 'Application No. 20050124049', 'Application No. 20090029424', 'Application No. 20080311632', 'Application No. 2003']

US Patent for Method for producing L-cysteine Patent (Patent # 9,234,223 issued January 12, 2016) - Justia Patents Search
Justia Patents Methionine; Cysteine; CystineUS Patent for Method for producing L-cysteine Patent (Patent # 9,234,223)
Method for producing L-cysteine
Mar 27, 2012 - AJINOMOTO CO., INC.
A method for producing L-cysteine and the like is provided by developing a novel technique for improving bacterial L-cysteine-producing ability. The method includes the steps of culturing a bacterium belonging to the genus Escherichia which has L-cysteine-producing ability, and in which expression of a gene involved in sulfite reduction is enhanced, in a medium containing thiosulfate, and collecting L-cysteine, a related substance thereof, or a mixture thereof which accumulate in the medium.
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application No. 61/470,573, filed Apr. 1, 2011, the entirety of which is incorporated by reference herein. Also, the Sequence Listing filed electronically herewith is hereby incorporated by reference (File name: 2012-03-27T_US-464_Seq_List; File size: 88 KB; Date recorded: Mar. 27, 2012).
The present invention relates to a method for producing L-cysteine or a related substance thereof. L-cysteine and related substances thereof are used in the fields of drugs, cosmetics, and foods.
L-cysteine is conventionally obtained by extraction from keratin-containing substances such as hair, horns, and feathers, or converting the precursor DL-2-aminothiazoline-4-carboxylic acid using a microbial enzyme. L-cysteine can also be produced on a large scale by an immobilized enzyme method utilizing a novel enzyme. Furthermore, L-cysteine can also be produced by fermentation utilizing a microorganism.
The ability of a microorganism to produce L-cysteine can be improved by enhancing the activity of an enzyme of the L-cysteine biosynthesis pathway, or an activity of an enzyme involved in generation of a compound which acts as a substrate of that pathway, such as L-serine. Microorganisms which are able to produce L-cysteine include, for example, a coryneform bacterium in which intracellular serine acetyltransferase activity is increased (Japanese Patent Laid-open (Kokai) No. 2002-233384). L-cysteine-producing ability can also be increased by incorporating a serine acetyltransferase which has been mutated so that feedback inhibition by L-cysteine is attenuated (Japanese Patent Laid-open (Kokai) No. 11-155571, U.S. Patent Published Application No. 20050112731 and U.S. Pat. No. 6,218,168). A mutant serA gene coding for a mutant 3-phosphoglycerate dehydrogenase of which feedback inhibition by serine is attenuated is also known, and use thereof in production of L-cysteine by Escherichia coli has been suggested (U.S. Pat. No. 5,856,148 and U.S. Patent Published Application No. 20050009162).
Furthermore, L-cysteine-producing ability of a microorganism can also be improved by suppressing the system which acts to decompose L-cysteine. Microorganisms in which this system has been suppressed, and the L-cysteine-producing ability is enhanced, include coryneform bacteria or Escherichia bacteria in which activity of cystathionine-β-lyase (Japanese Patent Laid-open (Kokai) No. 11-155571), tryptophanase (Japanese Patent Laid-open (Kokai) No. 2003-169668), or O-acetylserine sulfhydrylase B (Japanese Patent Laid-open (Kokai) No. 2005-245311) is attenuated or deleted.
Moreover, L-cysteine-producing ability of a microorganism can also be improved by enhancing the L-cysteine-secreting ability. For example, techniques have been reported of enhancing L-cysteine-producing ability by enhancing expression of the ydeD gene (Dassler et al., Mol. Microbiol., 36, 1101-1112 (2000)), yfiK gene (Macdonald and Cole, Molecular and General Genetics, 200(2):328-334 (1985)), or yeaS gene (Warren et al., Biochemical Journal, 265(3):725-729 (1990)), which codes for a protein that participates in secretion of L-cysteine. Furthermore, techniques have been reported of enhancing L-cysteine-producing ability by enhancing expression of the mar locus, emr locus, acr locus, cmr locus, mex gene, bmr gene or qacA gene (U.S. Pat. No. 5,972,663), or emrAB, emrKY, yojIH, acrEF, bcr or cusA gene (Japanese Patent Laid-open (Kokai) No. 2005-287333). These loci/genes encode proteins which are responsible for secreting a substance which is cytotoxic from the cells.
L-cysteine is a sulfur-containing amino acid, and therefore, metabolism of a sulfur source is involved in the production of L-cysteine. The biosynthesis pathway of L-cysteine when glucose is the carbon source and the sulfate or thiosulfate ion is the sulfur source, and examples of genes involved in that pathway are shown in FIG. 1.
Sulfite reductase is an enzyme that catalyzes, in the sulfate reduction pathway (Frederich C., Neidhardt et al., Escherichia Coli and Salmonella Cellular and Molecular Biology, 2nd Edition, Vol. 1, ASM Press, 514-527) in which sulfate ion (SO42−) is converted into sulfide ion (—S2−), the reaction of reducing sulfite ion (—SO32−) into sulfide ion (—S2−) as the final step. The sulfide ion generated from the sulfate ion via the sulfate reduction pathway reacts with O-acetylserine (OAS) to generate L-cysteine. That is, when L-cysteine is produced with sulfate ions as the sulfur source, the sulfite reductase is considered to be one of the enzymes that participate in the L-cysteine biosynthesis. It is known that the sulfite reductase of Escherichia coli has an α8β4 complex structure which includes a subunits encoded by the cyst gene and β subunits encoded by the cysI gene. Furthermore, the cysG gene codes for the biosynthesis enzyme of siroheme, which is a cofactor of the sulfite reductase β subunit. The cysJ gene and the cysI gene are present on the same operon, whereas the cysG gene is on a different site of the genome. The details of the cysJ gene, the cysI gene and the proteins encoded by these genes are described in Ostrowski et al., Journal of Biological Chemistry, 264(27):15796-15808 (1989), Li et al., Gene, 53(2-3):227-234 (1987), Gaudu and Fontecave, European Journal of Biochemistry, 226 (2):459-463 (1994), Eschenbrenner et al., Journal of Biological Chemistry, 270(35):20550-20555 (1995) and Ostrowski et al., Journal of Biological Chemistry, 264(26):15726-15737 (1989). Furthermore, the details of the cysG gene and the protein encoded by this gene are described in Peakman et al., European Journal of Biochemistry, 191(2):315-323 (1990), Macdonald and Cole, Molecular and General Genetics, 200(2):328-334 (1985), Warren et al., Biochemical Journal, 265(3):725-729 (1990) and Spencer et al., FEBS Letters 335(1):57-60 (1993).
Although there has been no report directly linking enhancing expression of the cysG gene, cysJ gene or cysI gene with increased L-cysteine production, an Escherichia coli bacteria in which activity of a protein encoded by the cysB gene is enhanced is known as an L-cysteine-producing bacterium (International Patent Publication WO01/27307). Because the protein encoded by the cysB gene positively regulates expression of the cysJIH operon which includes the cysJ gene and cysI gene coding for sulfite reductase, expression of the cysJ gene and cysI gene may be increased in that Escherichia coli. On the other hand, expression of the cysG gene is not regulated by the protein encoded by the cysB gene, and enhancement of expression of the cysG gene for L-cysteine production has not been reported.
Furthermore, the effectiveness of enhancing expression of the cysG gene, cysJ gene or cysI gene in the production of amino acids other than L-cysteine has been suggested. For example, enhancing expression of the cys genes including the cysG gene, cysJ gene and cysI gene, is referred to concerning production of L-threonine or L-lysine (U.S. Pat. No. 7,759,094), production of L-threonine (International Patent Publication WO03/006666), and production of L-methionine (U.S. Patent Published Application No. 2009298136 and International Patent Publication WO2008/127240). Furthermore, enhancing expression of the cys genes including the cysJ gene and the cysI gene is also referred to concerning production of L-methionine (International Patent Publication WO2009/043372, International Patent Publication WO2005/108561, International Patent Publication WO2007/077041, and International Patent Publication WO2006/082254). Moreover, enhancing expression of the cysJIH operon including the cysJ gene and the cysI gene is also referred to concerning production of L-methionine (U.S. Patent Published Application No. 20100047879). Furthermore, increasing L-arginine production by enhancing expression of the cysG gene has been reported (U.S. Patent Published Application No. 20050069994).
On the other hand, thiosulfate is metabolized in a pathway other than the sulfate reduction pathway (FIG. 1), and it is not known whether sulfite reductase participates in the metabolism of thiosulfate. Furthermore, all the aforementioned findings concerning production of amino acids fail to suggest that enhancing expression of the cysG gene, cysJ gene or cysI gene can be effective for amino acid production using thiosulfate as the sulfur source. As described above, the relationship between production of an amino acid such as L-cysteine using thiosulfate as the sulfur source and the cysG gene, cysJ gene or cysI gene has not been previously reported.
An aspect of the present invention is to provide a method for producing L-cysteine, a related substance thereof, or a mixture thereof by developing a novel technique for improving L-cysteine-producing ability of a bacterium.
It is an aspect of the present invention to provide a method of improving production of L-cysteine when thiosulfate is used as the sulfur source, in a bacterium by modifying the bacterium so that expression of a gene involved in the sulfite reduction is increased.
It is an aspect of the present invention to provide a method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
culturing a bacterium belonging to the genus Escherichia in a medium comprising thiosulfate, which bacterium has L-cysteine-producing ability and is modified so that expression of a gene involved in sulfite reduction is increased; and
collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium.
It is a further aspect of the present invention to provide a method as described above, wherein the gene involved in sulfite reduction is a gene selected from the group consisting of the cysG gene, the cysJ gene, and the cysI gene.
It is a further aspect of the present invention to provide a method as described above, wherein expression of at least the cysG gene is increased.
It is a further aspect of the present invention to provide a method as described above, wherein expression of the cysG gene, the cysJ gene, and the cysI gene is increased.
It is a further aspect of the present invention to provide a method as described above, wherein expression of the gene involved in sulfite reduction is increased by increasing copy number of the gene involved in sulfite reduction, or by modifying an expression control sequence of the gene.
It is a further aspect of the present invention to provide a method as described above, wherein the bacterium is Escherichia coli.
It is a further aspect of the present invention to provide a method as described above, wherein the bacterium further has a characteristic selected from the group consisting of:
(a) biosynthesis system of L-cysteine is enhanced,
(b) secretion system of L-cysteine is enhanced.
It is a further aspect of the present invention to provide a method as described above, wherein the related substance is L-cystine or a thiazolidine derivative.
According to the present invention, L-cysteine-producing ability of a bacterium can be improved when thiosulfate is used as a sulfur source. Furthermore, according to the present invention, L-cysteine, a related substance thereof, or a mixture thereof can be efficiently produced when thiosulfate is used as a sulfur source.
FIG. 1 shows an outline of the biosynthesis pathway of L-cysteine when glucose is used as the carbon source, and sulfate ion or thiosulfate ion is used as the sulfur source, and examples of the genes which are involved.
FIG. 2 shows the nucleotide sequence (SEQ ID NO: 51) of the ligation site of a wild-type promoter Pnlp0 of the nlpD gene and a gene ligated downstream thereof, and the nucleotide sequence (SEQ ID NO: 52) of ligation site of a mutant type promoter Pnlp8 of the nlpD gene and a gene ligated downstream thereof.
FIG. 3 shows the disposition of primers in the production of a cysEX gene fragment.
FIG. 4 shows the structure of the plasmid pACYC-DES.
The bacterium which can be used in accordance with the presently described invention (henceforth also referred to as the bacterium of the present invention) is a bacterium belonging to the genus Escherichia which is able to produce L-cysteine, and is modified so that expression of a gene involved in sulfite reduction is increased.
L-cysteine can be in free form, a salt thereof, or a mixture of these. Examples of the salt include, for example, sulfate, hydrochloride, carbonate, ammonium salt, sodium salt, and potassium salt.
The L-cysteine-producing ability can refer to an ability of a bacterium to produce and cause accumulation of L-cysteine, a related substance thereof, or a mixture of these, in the medium or the cells of the bacterium in such an amount that L-cysteine, the related substance thereof, or the mixture of these can be collected from the medium or cells, when the bacterium is cultured in the medium. A bacterium having L-cysteine-producing ability can mean a bacterium that can produce and accumulate L-cysteine, a related substance thereof, or a mixture of these in a medium in a larger amount compared with a wild-type strain or a parent strain. A bacterium having L-cysteine-producing ability can mean a bacterium that can produce and accumulate L-cysteine, a related substance thereof, or a mixture of these in a medium in an amount of 0.05 g/L or more, 0.1 g/L or more, 0.2 g/L or more, or even 0.4 g/L or more.
A portion of the L-cysteine produced by the bacterium can be converted into L-cystine in the medium by formation of a disulfide bond. Further, S-sulfocysteine may be generated by the reaction of L-cysteine and thiosulfate contained in the medium (Szczepkowski T. W., Nature, vol. 182 (1958)). Furthermore, L-cysteine generated in bacterial cells may be condensed with a ketone or aldehyde, for example, pyruvic acid, which is present in the cells, to produce a thiazolidine derivative via a hemithioketal as an intermediate (refer to Japanese Patent No. 2992010). These thiazolidine derivative and hemithioketal may exist as an equilibrated mixture.
Furthermore, L-cysteine can be used as a starting material in the biosyntheses of γ-glutamylcysteine, glutathione, cystathionine, homocysteine, L-methionine, S-adenosylmethionine, and so forth. Therefore, by using a bacterium having an ability to produce any of these compounds via L-cysteine in addition to the ability to produce L-cysteine, these compounds can be produced.
Therefore, the L-cysteine-producing ability is not limited to an ability to produce and accumulate only L-cysteine in a medium or cells, but also includes an ability to produce and accumulate L-cysteine, L-cystine, a derivative of L-cysteine as mentioned above (for example, S-sulfocysteine, a thiazolidine derivative, and a hemithioketal), a compound which is produced via L-cysteine as mentioned above (for example, γ-glutamylcysteine, glutathione, cystathionine, homocysteine, L-methionine, and S-adenosylmethionine), or a mixture of these in the medium or cells, L-cystine, a derivative of L-cysteine as mentioned above, and a compound produced via L-cysteine as mentioned above can be collectively referred to as a related substance of L-cysteine.
The bacterium having L-cysteine-producing ability can inherently have L-cysteine-producing ability, or it may be obtained by modifying a microorganism such as those described below by mutagenesis or a recombinant DNA technique so that it acquires L-cysteine-producing ability.
The bacterium is not particularly limited, so long as it is a bacterium belonging to the genus Escherichia and having L-cysteine-producing ability. Specifically, those classified into the genus Escherichia according to the taxonomy used in the NCBI (National Center for Biotechnology Information) database (www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id91347) can be used.
Although the Escherichia bacteria are not particularly limited, specifically, those described in the work of Neidhardt et al. (Backmann B. J., 1996, Derivations and Genotypes of some mutant derivatives of Escherichia coli K-12, p. 2460-2488, Table 1, In F. D. Neidhardt (ed.), Escherichia coli and Salmonella Cellular and Molecular Biology/Second Edition, American Society for Microbiology Press, Washington, D.C.) can be used. Examples of Escherichia bacteria include, for example, Escherichia coli. Specific examples of Escherichia coli include the Escherichia coli W3110 strain (ATCC 27325), Escherichia coli MG1655 strain (ATCC 47076) and so forth, which are derived from the prototype wild-type strain, K12.
These strains are available from, for example, the American Type Culture Collection (Address: P.O. Box 1549, Manassas, Va. 20108, United States of America). That is, registration numbers are given to each of the strains, and the strains can be ordered by using these registration numbers (refer to www.atcc.org/). The registration numbers of the strains are listed in the catalogue of the American Type Culture Collection.
Methods for imparting L-cysteine-producing ability to bacteria belonging to the genus Escherichia and methods for enhancing L-cysteine-producing ability of such bacteria are described below.
To impart L-cysteine-producing ability to a bacterium, methods conventionally employed in the breeding of coryneform bacteria, Escherichia bacteria, and so forth can be used. Such methods include acquiring an auxotrophic mutant strain, an analogue resistant strain, or a metabolic regulation mutant strain, or constructing a recombinant strain in which an L-cysteine biosynthesis enzyme is overexpressed, and so forth (see “Amino Acid Fermentation”, Gakkai Shuppan Center (Ltd.), 1st Edition, published May 30, 1986, pp. 77-100). In the breeding of L-cysteine-producing bacteria, one or more kinds of the above-described properties such as auxotrophy, analogue resistance, and metabolic regulation mutation can be imparted. Also, expression of one or more of the L-cysteine biosynthesis enzymes can be enhanced. Furthermore, imparting such properties as auxotrophy, analogue resistance, and metabolic regulation mutation can be combined with enhancing a biosynthesis enzyme.
An auxotrophic mutant strain, L-cysteine analogue resistant strain, or metabolic regulation mutant strain having L-cysteine-producing ability can be obtained by subjecting a parent strain or wild-type strain to conventional mutagenesis, such as exposure to X-rays or UV irradiation or a treatment with a mutagen such as N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) or ethyl methanesulfonate (EMS), and then selecting a strain exhibiting autotrophy, analogue resistance or a metabolic regulation mutation and having L-cysteine-producing ability from the obtained mutant strains.
Methods for imparting L-cysteine-producing ability to bacteria belonging to the genus Escherichia or enhancing L-cysteine-producing ability of such bacteria, and bacteria having L-cysteine-producing ability are specifically exemplified below.
<Impartation or Enhancement of L-Cysteine-Producing Ability, and L-Cysteine-Producing Bacteria>
L-Cysteine-producing ability of a bacterium can be imparted or enhanced by enhancing the biosynthesis system of L-cysteine. “To enhance the biosynthesis system of L-cysteine” can mean, for example, to enhance activity of an enzyme involved in the biosynthesis of L-cysteine. Examples of enzymes involved in the biosynthesis of L-cysteine include enzymes of the L-cysteine biosynthesis pathway and enzymes involved in synthesis of a compound which acts as a substrate in the L-cysteine biosynthesis pathway, such as L-serine, and specific examples include serine acetyltransferase (SAT) and 3-phosphoglycerate dehydrogenase (PGD). Enhancement of an enzymatic activity can be attained by enhancing expression of a gene coding for the objective enzyme, or by enhancing specific activity of the objective enzyme, as described later. Because serine acetyltransferase is inhibited by feedback inhibition by L-cysteine, the enzymatic activity of this enzyme can be enhanced by, in particular, incorporating a mutant type cysE gene coding for serine acetyltransferase of which feedback inhibition is attenuated or eliminated into a bacterium. Furthermore, because 3-phosphoglycerate dehydrogenase is inhibited by feedback inhibition by serine, the enzymatic activity of this enzyme can be enhanced by, in particular, incorporating a mutant type serA gene coding for a mutant 3-phosphoglycerate dehydrogenase of which feedback inhibition is attenuated or eliminated into a bacterium.
Mutant SATs which are derived from Escherichia coli and are resistant to feedback inhibition include the following mutations: replacement of the methionine residue at position 256 with a glutamate residue (Japanese Patent Laid-open No. 11-155571), replacement of the methionine residue at position 256 with an isoleucine residue (Denk, D. and Boeck, A., J. General Microbiol., 133, 515-525 (1987)), a mutation in the region from the amino acid residue at position 97 to the amino acid residue at position 273 or deletion of the C-terminus region from the amino acid residue at position 227 (International Patent Publication WO97/15673, U.S. Pat. No. 6,218,168), one or more mutations in the amino acid sequence corresponding to positions 89 to 96 of wild-type SAT, wherein a mutant SAT including the mutation(s) is desensitized to feedback inhibition by L-cysteine (U.S. Patent Published Application No. 20050112731(A1)), replacement of the Val residue and the Asp residue at positions 95 and 96 of wild-type SAT with Arg residue and Pro residue, respectively (name of the mutant gene: cysE5, U.S. Patent Published Application No. 20050112731(A1)), replacement of the threonine residue at position 167 with an alanine residue (U.S. Pat. No. 6,218,168, U.S. Patent Published Application No. 20050112731(A1)), and so forth.
The gene coding for SAT is not limited to the gene derived from Escherichia coli, and any gene coding for a protein having the SAT activity can be used. For example, an SAT isozyme of Arabidopsis thaliana desensitized to feedback inhibition by L-cysteine is known, and the gene encoding this SAT can also be used (FEMS Microbiol. Lett., 179, 453-459 (1999)).
Furthermore, the serA5 gene is known to code for a mutant PGD resistant to feedback inhibition by serine (U.S. Pat. No. 6,180,373).
Furthermore, L-cysteine-producing ability of a bacterium can also be improved by enhancing the L-cysteine secretion system. The L-cysteine secretion system can be enhanced by enhancing expression of a gene coding for one or more proteins involved in secretion of L-cysteine. Examples of proteins involved in secretion of L-cysteine include the YdeD protein encoded by the ydeD gene, the YfiK protein encoded by the yfiK gene, and the YeaS protein encoded by the yeaS gene. Therefore, by enhancing expression of the ydeD gene (Dassler et al., Mol. Microbiol., 36, 1101-1112 (2000)), the yfiK gene (Japanese Patent Laid-open (Kokai) No. 2004-49237) or the yeaS gene (European Patent Laid-open No. 1016710), L-cysteine-producing ability can be enhanced. Furthermore, by introducing a mutation into the threonine residue of the position 28, the phenylalanine residue of the position 137, and/or the leucine residue of the position 188 of the YeaS protein, the L-cysteine secretion system is also enhanced, and L-cysteine-producing ability can be enhanced (European Patent Laid-open No. 2218729). Specifically, replacing the threonine residue at position 28 with asparagine residue, replacing the phenylalanine residue at position 137 with serine, glutamine, alanine, histidine, cysteine or glycine residue, and/or replacing the leucine residue at position 188 with glutamine residue in the YeaS protein are particular examples (European Patent Laid-open No. 2218729).
Furthermore, proteins which are able to secrete a substance which is cytotoxic include those involved in secretion of L-cysteine. Therefore, by enhancing expression of a gene coding for any one of them, the L-cysteine secretion system can be enhanced. For example, by increasing expression of the mar locus, emr locus, acr locus, cmr locus, mex gene, bmr gene or qacA gene (U.S. Pat. No. 5,972,663), or emrAB, emrKY, yojIH, acrEF, bcr or cusA gene (Japanese Patent Laid-open (Kokai) No. 2005-287333), which encode proteins which secrete a substance which is cytotoxic from cells, L-cysteine-producing ability can be enhanced.
Furthermore, the L-cysteine-producing ability can also be improved by enhancing the sulfate/thiosulfate transport system. The sulfate/thiosulfate transport system proteins are encoded by the cysPTWAM cluster genes (Japanese Patent Laid-open (Kokai) No. 2005-137369, European Patent No. 1528108).
Furthermore, the L-cysteine-producing ability of a bacterium can be improved by reducing the activity of cysteine desulfhydrase, which contributes to decomposition of L-cysteine. Proteins having the cysteine desulfhydrase activity of Escherichia coli include cystathionine-β-lyase encoded by the metC gene (Japanese Patent Laid-open (Kokai) No. 11-155571, Chandra et al., Biochemistry, 21, 3064-3069 (1982)), tryptophanase encoded by the tnaA gene (Japanese Patent Laid-open (Kokai) No. 2003-169668, Austin Newton et al., J. Biol. Chem., 240, 1211-1218 (1965)), O-acetylserine sulfhydrylase B encoded by the cysM gene (Japanese Patent Laid-open (Kokai) No. 2005-245311) and MalY encoded by the malY gene (Japanese Patent Laid-open (Kokai) No. 2005-245311). The enzymatic activity can be reduced by the methods described herein.
The L-cysteine-producing bacterium can have one of the aforementioned properties for improving L-cysteine-producing ability, or two or more of them in any combination. For example, in the L-cysteine-producing bacterium, either the biosynthesis system of L-cysteine or the secretion system of L-cysteine can be enhanced, and both can be enhanced.
Specific examples of L-cysteine-producing bacteria include, but are not limited to, Escherichia bacteria such as the E. coli JM15 strain transformed with multiple kinds of cysE gene alleles encoding serine acetyltransferase (SAT) resistant to feedback inhibition (U.S. Pat. No. 6,218,168), E. coli W3110 strain in which a gene encoding a protein suitable for secretion of a cytotoxic substance is overexpressed (U.S. Pat. No. 5,972,663), E. coli in which cysteine desulfhydrase activity is decreased (Japanese Patent Laid-open (Kokai) No. 11-155571), and E. coli W3110 strain in which activity of the positive transcriptional control factor of the cysteine regulon encoded by the cysB gene is increased (WO01/27307), E. coli having the plasmid pACYC-DES (Japanese Patent Laid-open (Kokai) No. 2005-137369 (U.S. Patent Published Application No. 20050124049(A1), European Patent Laid-open No. 1528108(A1))) containing the ydeD gene, a mutant cysE gene, and a mutant serA5 gene, and so forth. pACYC-DES is a plasmid obtained by inserting the above three kinds of genes into pACYC184, and expression of each of the genes is controlled by the PompA promoter.
The ability to produce compounds biosynthesized from L-cysteine as a starting material, such as γ-glutamylcysteine, glutathione, cystathionine, homocysteine, L-methionine and S-adenosylmethionine, can also be imparted or enhanced by enhancing activity of an enzyme of biosynthesis system of an objective compound, or reducing activity of an enzyme of a pathway branching from the biosynthesis system of an objective compound, or reducing the activity of an enzyme that decomposes an objective compound.
For example, the ability to produce γ-glutamylcysteine can be enhanced by enhancing the γ-glutamylcysteine synthetase activity, and/or reducing the glutathione synthetase activity. Furthermore, the ability to produce glutathione can be imparted or enhanced by enhancing the γ-glutamylcysteine synthetase activity and/or the glutathione synthetase activity. Furthermore, by using a γ-glutamylcysteine synthetase which has been mutated to be resistant to feedback inhibition by glutathione, the ability to produce γ-glutamylcysteine or glutathione can be enhanced. Production of glutathione is described in detail in the overview of Li et al. (Yin Li, Gongyuan Wei, Jian Chen, Appl. Microbiol. Biotechnol., 66:233-242 (2004)).
The ability to produce L-methionine can be imparted or enhanced by imparting L-threonine auxotrophy or norleucine resistance (Japanese Patent Laid-open (Kokai) No. 2000-139471). In E. coli, the genes encoding the enzymes involved in the biosynthesis of L-threonine exist as the threonine operon (thrABC), and an L-threonine auxotrophic strain that has lost the biosynthesis ability for L-homoserine and the following compounds can be obtained by, for example, deleting the thrBC moiety. In a norleucine resistant strain, the S-adenosylmethionine synthetase activity can be attenuated, and L-methionine-producing ability can be imparted or enhanced. In E. coli, S-adenosylmethionine synthetase is encoded by the metK gene. The ability to produce L-methionine can also be imparted or enhanced by deleting the methionine repressor or enhancing the activity of an enzyme involved in L-methionine biosynthesis, such as homoserine transsuccinylase, cystathionine γ-synthase and aspartokinase-homoserine dehydrogenase II (Japanese Patent Laid-open (Kokai) No. 2000-139471). In E. coli, the methionine repressor is encoded by the metJ gene, homoserine transsuccinylase is encoded by the metA gene, cystathionine γ-synthase is encoded by the metB gene, and aspartokinase-homoserine dehydrogenase II is encoded by the metL gene. Furthermore, by using a homoserine transsuccinylase which has been mutated to be resistant to feedback inhibition by L-methionine, the ability to produce L-methionine can also be imparted or enhanced (Japanese Patent Laid-open (Kokai) No. 2000-139471, U.S. Patent Published Application No. 20090029424). Because L-methionine is biosynthesized via L-cysteine as an intermediate, the ability to produce L-methionine can also be improved by improving the ability to produce L-cysteine (Japanese Patent Laid-open (Kokai) No. 2000-139471, U.S. Patent Published Application No. 20080311632). Therefore, to impart or enhance the ability to produce L-methionine, it can also be effective to impart or enhance the ability to produce L-cysteine.
Specific examples of bacteria that produce L-methionine include E. coli strains such as AJ11539 (NRRL B-12399), AJ11540 (NRRL B-12400), AJ11541 (NRRL B-12401), AJ11542 (NRRL B-12402) (British Patent No. 2075055), 218 strain resistant to norleucine, which is an analogue of L-methionine (VKPM B-8125, Russian Patent No. 2209248), and 73 strain (VKPM B-8126, Russian Patent No. 2215782).
Furthermore, the strain AJ13425 (FERM P-16808, Japanese Patent Laid-open (Kokai) No. 2000-139471), which is derived from the E. coli W3110, can also be used to produce L-methionine. AJ13425 is an L-threonine auxotrophic strain in which the methionine repressor is deleted, intracellular S-adenosylmethionine synthetase activity is attenuated, and intracellular homoserine transsuccinylase activity, cystathionine γ-synthase activity, and aspartokinase-homoserine dehydrogenase II activity are enhanced. AJ13425 was deposited on May 14, 1998 at the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository, Address: Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan), and assigned an accession number of FERM P-16808.
Because cystathionine and homocysteine are intermediates in the L-methionine biosynthesis pathway, it can be effective to partially use the aforementioned L-methionine enhancing methods to enhance production of these substances. Specifically for enhancing cystathionine production, a methionine-auxotrophic mutant strain (Japanese Patent Application No. 2003-010654) and a method of adding cysteine (or raw material for biosynthesis thereof) and/or homoserine (or raw material for biosynthesis thereof) to a fermentation medium (Japanese Patent Laid-open (Kokai) No. 2005-168422) can be used. Since homocysteine is produced by using cystathionine as a precursor, the aforementioned methods for enhancing cystathionine production are also effective for enhancing homocysteine production.
Furthermore, the ability to produce compounds produced from a starting material of L-methionine, such as S-adenosylmethionine, can also be imparted or enhanced by enhancing activity of an enzyme of the biosynthesis system of the objective compound, or reducing the activity of an enzyme of a pathway branching away from the biosynthesis pathway of the objective compound or an enzyme that decomposes the objective compound. For example, the ability to produce S-adenosylmethionine can be imparted or enhanced by enhancing the methionine adenosyltransferase activity (European Patent Laid-open Nos. 0647712 and 1457569) or enhancing the secretion factor MdfA encoded by the mdfA gene (U.S. Pat. No. 7,410,789).
Methods for increasing enzymatic activities of SAT and so forth and reducing enzymatic activities of cysteine desulfhydrase and so forth are exemplified below.
<Method for Increasing Enzymatic Activity>
The expression “enzymatic activity is increased” can mean that the objective enzymatic activity is increased compared with that of a non-modified strain such as a wild-type strain or a parent strain. Although the degree of increase of the enzymatic activity is not particularly limited so long as the enzymatic activity is increased compared with a non-modified strain, the enzymatic activity is increased 1.5 times or more, 2 times or more, or even 3 times or more, compared with that of a non-modified strain. Furthermore, when “enzymatic activity is increased”, this includes not only when the objective enzymatic activity is increased in a strain which has the native objective enzymatic activity, but also when the objective enzymatic activity is imparted to a strain which does not have the native objective enzymatic activity. Moreover, so long as the objective enzymatic activity is increased as a result, an enzyme that is originally present in a bacterium may be attenuated or deleted, and then an appropriate enzyme may be also introduced.
Modification for increasing enzymatic activity may be attained by, for example, enhancing expression of a gene coding for the objective enzyme. The expression “enhancing or enhancement of expression of a gene” can have the same meaning as “increase of expression of a gene”.
Enhancement of expression of a gene can be attained by, for example, increasing the copy number of the gene.
The copy number of the objective gene can be increased by introducing the gene into a chromosome. A gene can be introduced into a chromosome by, for example, using homologous recombination. For example, a large number of copies of a gene can be introduced into a chromosome by homologous recombination for a target sequence that is present on the chromosome in a large copy number. Examples of such target sequences include, but are not limited to, repetitive DNA and inverted repeats which are present at the both ends of a transposon. The objective gene can be ligated to the side of a gene coding for the objective enzyme on a chromosome in tandem or can also be introduced into an unnecessary gene on a chromosome so that the objective gene overlaps with the unnecessary gene. Such gene introduction can be attained by using a temperature sensitive vector or by using an integration vector. Alternatively, as disclosed in U.S. Pat. No. 5,595,889, it is also possible to incorporate the objective gene into a transposon, and allow it to be transferred to a chromosomal DNA to introduce a large number of copies of the gene. As the transposon, for example, Mu, Tn10 and Tn5 can be used. Whether an objective gene has been introduced into a chromosome can be confirmed by Southern hybridization using a part of the objective gene as a probe.
Furthermore, the copy number of an objective gene can also be increased by introducing a vector containing the gene into the host bacterium. For example, the copy number of an objective gene can be increased by ligating a DNA fragment containing the objective gene with a vector that functions in the host bacterium to construct an expression vector of the objective gene, and transforming the host bacterium with the expression vector. As the vector, a vector autonomously replicable in the cell of the host bacterium can be used. The vector can be a multi-copy vector. Furthermore, the vector can have a marker such as an antibiotic resistance gene for selection of the transformants. Examples of vectors autonomously replicable in Escherichia coli cells include pUC19, pUC18, pHSG299, pHSG399, pHSG398, pACYC184, pBR322, pSTV29 (all of these are available from Takara Bio), pMW219 (NIPPON GENE), pTrc99A (Pharmacia), pPROK series vectors (Clontech), pKK233-2 (Clontech), pET series vectors (Novagen), pQE series vectors (QIAGEN), broad host spectrum vector RSF1010, and so forth.
Furthermore, expression of a gene can be enhanced by improving transcription efficiency of the gene. Transcription efficiency of a gene can be improved by, for example, substituting a stronger promoter for the native promoter of the gene on the chromosome. A “stronger promoter” can mean a promoter that improves the transcription of the gene compared to the wild-type promoter. As a stronger promoter, for example, known high expression promoters, such as T7 promoter, trp promoter, lac promoter, tac promoter, and PL promoter, can be used. Furthermore, as the stronger promoter, a highly-active promoter may be obtained by using various reporter genes. For example, the −35 and −10 regions in the promoter region can be made so they are more similar to the consensus sequence, and hence the activity of the promoter can be enhanced (International Patent Publication WO00/18935). Methods for evaluating the strength of promoters and examples of strong promoters are described in the paper of Goldstein et al. (Prokaryotic Promoters in Biotechnology, Biotechnol. Annu. Rev., 1, 105-128 (1995)), and so forth.
Furthermore, gene expression can also be enhanced by improving the translation efficiency of the gene. Translation efficiency of a gene can be improved by, for example, replacing the SD sequence (also referred to as the ribosome binding site (RBS)) on the chromosome with a stronger SD sequence. The “stronger SD sequence” can mean a SD sequence that provides improved translation of mRNA compared to the wild-type SD sequence. Examples of a stronger SD sequence include, for example, the RBS of the gene 10 derived from phage T7 (Olins P. O. et al, Gene, 1988, 73, 227-235). Furthermore, it is known that substitution, insertion, or deletion of several nucleotides in the spacer region between RBS and the start codon, especially in the sequence immediately upstream of the start codon (5′-UTR), can significantly affect the stability and translation efficiency of the mRNA, and hence the translation efficiency of a gene can also be improved by such a modification.
Regions affecting gene expression, such as the promoter, SD sequence, and spacer region between RBS and the start codon, are also generically called “expression control regions” or “expression control sequences”. An expression control region can be determined by using a promoter-search vector or gene analysis software such as GENETYX. Such expression control regions can be modified by, for example, a method using a temperature sensitive vector or the Red driven integration method (WO2005/010175).
Further, expression of an objective gene can also be enhanced by amplifying a regulator that increases expression of the gene, or deleting or attenuating a regulator that reduces expression of the gene. Examples of such regulators include, for example, those belonging to the LysR family, and so forth, and they can be found by using a database, such as EcoCyc (ecocyc.org/), or the like. A regulator can be modified by monitoring the increase of the transcription amount of the objective gene, or the increase of the amount of the objective protein, as an index.
Such methods for enhancing gene expression as mentioned above may be used independently or in an arbitrary combination.
Furthermore, a modification that increases enzymatic activity can also be attained by, for example, enhancing specific activity of the objective enzyme. An enzyme having enhanced specific activity can be obtained by, for example, searching various bacteria. Furthermore, a highly-active enzyme may also be obtained by introducing a mutation into the enzyme. Enhancement of specific activity may be independently used, or may be used in an arbitrary combination with such methods for enhancing gene expression as mentioned above.
The method of the transformation is not particularly limited, and conventionally known methods can be used. For example, methods of treating recipient cells with calcium chloride so as to increase permeability thereof for DNA, which has been reported for Escherichia coli K-12 strain (Mandel, M. and Higa, A., J. Mol. Biol., 53:159-162 (1970)), and methods of preparing competent cells from cells which are at the growth phase, followed by transformation with DNA, which has been reported for Bacillus subtilis (Duncan, C. H., Wilson, G. A. and Young, F. E., Gene, 1, 153 (1977)) can be used. Alternatively, a method of making DNA-recipient cells into protoplasts or spheroplasts, which can easily take up recombinant DNA, followed by introducing a recombinant DNA into the cells, which is known to be applicable to Bacillus subtilis, actinomycetes and yeasts (Chang, S, and Choen, S. N., 1979, Molec. Gen. Genet., 168:111 (1979); Bibb, M. J., Ward, J. M. and Hopwood, O. A., Nature, 274, 398 (1978); Hinnen, A., Hicks, J. B. and Fink, G. R., Proc. Natl. Acad. Sci. USA, 75, 1929 (1978)), can be used.
Increase of the objective enzymatic activity can be confirmed by measuring the enzymatic activity.
Increase of the transcription amount of an objective gene can be confirmed by comparing the amount of mRNA transcribed from the gene with that of a wild-type strain or a non-modified strain. Examples of methods for evaluating amount of mRNA include Northern hybridization, RT-PCR, and so forth (Molecular Cloning, Cold spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001).
Increase of the amount of the objective protein can be confirmed by Western blotting using an antibody (Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (USA), 2001).
<Methods for Reducing Enzymatic Activity>
The expression “enzymatic activity is reduced” can mean that the enzymatic activity is decreased compared with that of a non-modified strain such as a wild-type strain or a parent strain, and includes when the activity has completely disappeared. Although the degree of the reduction of the enzymatic activity is not particularly limited so long as the activity is reduced compared with that of a non-modified strain, it can be reduced to, for example, 75% or less, 50% or less, 25% or less, or 10% or less compared with that of a non-modified strain, and the complete disappearance of the activity is an example. Depending on the type of enzyme, it may be better not to completely eliminate the enzymatic activity.
A modification for reducing the enzymatic activity can be attained by, for example, reducing expression of a gene coding for the objective enzyme. Expression of a gene can be reduced by, for example, modifying an expression control sequence, such as promoter and SD sequence, of the gene. When an expression control sequence is modified, one or more nucleotides, two or more nucleotides, or even three or more nucleotides, of the expression control sequence can be modified. Furthermore, a part or all of the expression control sequence can be deleted. Expression of a gene can also be reduced by expressing an antisense RNA.
A modification for reducing enzymatic activity can also be attained by, for example, deleting a part or all of a coding region of a gene coding for the objective enzyme on a chromosome. Furthermore, the whole gene, including the sequences upstream and downstream of the gene on the chromosome, may be deleted. The region to be deleted may be an N-terminus region, an internal region or a C-terminus region, so long as the enzymatic activity is reduced. Deletion of a longer region will usually more surely inactivate the gene. Furthermore, the reading frames upstream and downstream of the region to be deleted may not be the same.
A modification for reducing enzymatic activity can also be attained by introducing a mutation resulting in amino acid substitution (missense mutation), a stop codon (nonsense mutation), or a frame shift mutation which adds or deletes one or two nucleotides into a coding region of a gene coding for the objective enzyme on a chromosome (Journal of Biological Chemistry, 272:8611-8617 (1997); Proceedings of the National Academy of Sciences, USA, 95 5511-5515 (1998); Journal of Biological Chemistry, 266, 20833-20839 (1991)).
A modification for reducing the enzymatic activity can also be attained by inserting another sequence into a coding region of a gene coding for the objective enzyme on the chromosome. Such a sequence may be inserted into any region of the gene, and insertion of a longer sequence can more surely inactivate the objective gene. Reading frames upstream and downstream of the insertion site may not be the same. The other sequence is not particularly limited so long as a sequence which decreases or deletes function of the encoded protein is chosen, and examples include a marker gene such as antibiotic resistance genes, a gene useful for L-cysteine production, and so forth.
A gene on a chromosome can be modified as described above by, for example, preparing a deletion-type gene, in which a partial sequence of the gene is deleted so that the deletion-type gene does not produce a protein that can normally function, and then transforming a bacterium with a recombinant DNA containing the deletion-type gene to cause homologous recombination between the deletion-type gene and the native gene on the chromosome, which results in substitution of the deletion-type gene for the native gene on the chromosome. The above operation can be made easier by introducing a marker gene suitable for a characteristic of the host such as auxotrophy into the recombinant DNA. The protein encoded by the deletion-type gene has a conformation different from that of the wild-type protein, even if it is even produced, and thus the function is reduced or deleted. Such gene disruption based on gene substitution utilizing homologous recombination has already been established, and examples include the method called Red-driven integration (Datsenko, K. A., and Wanner, B. L., Proc. Natl. Acad. Sci. USA, 97:6640-6645 (2000)), methods using a linear DNA such as the method of utilizing Red driven integration in combination with an excision system derived from λ phage (Cho, E. H., Gumport, R. I., Gardner, J. F., J. Bacteriol., 184:5200-5203 (2002)) (refer to WO2005/010175), methods using a plasmid containing a temperature sensitive replication origin, methods using a plasmid capable of conjugative transfer, methods utilizing a suicide vector without a replication origin in a host (U.S. Pat. No. 6,303,383, Japanese Patent Laid-open (Kokai) No. 05-007491), and so forth.
A modification for reducing enzymatic activity can also be attained by, for example, mutagenesis. Examples of mutagenesis include exposure to UV irradiation or a treatment with a typical mutagen such as N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS) and methyl methanesulfonate (MMS).
Decrease of the enzymatic activity can be confirmed by measuring the enzymatic activity. The cysteine desulfhydrase activity can be measured by the method described in Japanese Patent Laid-open (Kokai) No. 2002-233384.
Decrease of the transcription amount of an objective gene can be confirmed by comparing the amount of the mRNA transcribed from the gene with that of a non-modified strain. Examples of methods for evaluating amount of mRNA include Northern hybridization, RT-PCR, and so forth (Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 2001).
Decrease of the amount of an objective protein can be confirmed by Western blotting using an antibody (Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA, 2001).
<Enhancement of Expression of Gene Involved in Sulfite Reduction>
The bacterium can be modified so that expression of one or more genes involved in sulfite reduction is increased. The bacterium can be obtained by modifying a bacterium belonging to the genus Escherichia and having L-cysteine-producing ability such as those mentioned above so that expression of a gene involved in sulfite reduction is increased. The bacterium can also be obtained by modifying a bacterium belonging to the genus Escherichia so that expression of a gene involved in sulfite reduction is increased, and then imparting or enhancing L-cysteine-producing ability.
Examples of the gene involved in sulfite reduction include a gene coding for a sulfite reductase. Sulfite reductase can refer to a protein having sulfite-reducing activity. The sulfite-reducing activity can mean an activity of catalyzing the reaction of reducing sulfite ion (—SO32−) into sulfide ion (—S2−). Examples of the gene coding for sulfite reductase include the cysJ gene and the cysI gene. The sulfite reductase of Escherichia coli is an NADPH-dependent sulfite reductase (EC 1.8.1.2), and it has an α8β4 complex structure which includes a subunits encoded by the cysJ gene and β subunits encoded by the cysI gene. Therefore, when a protein shows the sulfite-reducing activity, this can mean not only that the protein encoded by the gene shows sulfite-reducing activity by itself, but also that a complex including the protein as a subunit shows the sulfite-reducing activity.
Furthermore, examples of the gene involved in sulfite reduction can include a gene involved in the biosynthesis of a cofactor of sulfite reductase. Examples of the cofactor of sulfite reductase include siroheme used as a prosthetic group, and NADPH and flavin used as a coenzyme. Among these, siroheme is a particular example. Examples of the gene involved in the biosynthesis of siroheme include the cysG gene coding for siroheme synthetase. The protein encoded by the cysG gene has an activity of catalyzing conversion of uroporphyrinogen III (Uro′gen III) as an intermediate into siroheme.
The proteins encoded by the cysJ gene, cysI gene and cysG gene are also referred to as the CysJ protein, CysI protein and CysG protein, respectively.
The cysJ gene of the Escherichia coli K12 MG1655 strain corresponds to the complementary sequence of the sequence at positions 2888121 to 2889920 in the genome sequence registered at the NCBI database as GenBank accession NC—000913 (VERSION NC—000913.2 GI: 49175990). The cysJ gene of the Escherichia coli K12 MG1655 strain is synonymous with ECK2759 and JW2734. The CysJ protein of the Escherichia coli K12 MG1655 strain is registered as GenBank accession NP—417244 (version NP—417244.1 GI: 16130671, locus_tag=“b2764”).
The cysI gene of the Escherichia coli K12 MG1655 strain corresponds to the complementary sequence of the sequence at positions 2886409 to 2888121 of the genome sequence. The cysI gene of the Escherichia coli K12 MG1655 strain is synonymous with ECK2758 and JW2733. The CysI protein of the Escherichia coli K12 MG1655 strain is registered as GenBank accession NP—417243 (version NP—417243.1 GI: 16130670, locus_tag=“b2763”).
Furthermore, the cysG gene of the Escherichia coli K12 MG1655 strain corresponds to the sequence at positions 3495850 to 3497223 of the genome sequence. The cysG gene of the Escherichia coli K12 MG1655 strain is synonymous with ECK3356 and JW3331. The CysG protein of the Escherichia coli K12 MG1655 strain is registered as GenBank accession NP—417827 (version NP—417827.1 GI: 16131246, locus_tag=“b3368”).
The nucleotide sequences of the cysJ gene, cysI gene, and cysG gene of the MG1655 strain are shown as SEQ ID NOS: 39, 43 and 47, respectively. The amino acid sequences of the proteins encoded by these genes are shown as SEQ ID NOS: 40, 44 and 48, respectively. The nucleotide sequences of the cysJ gene, cysI gene and cysG gene of the Pantoea ananatis SC17 strain are shown as SEQ ID NOS: 41, 45 and 49, respectively. The amino acid sequences of the proteins encoded by these genes are shown as SEQ ID NOS: 42, 46 and 50, respectively. The Pantoea ananatis SC17 strain was deposited on Feb. 4, 2009 at the National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository (Address: Tsukuba Central 6, 1-1, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, 305-8566, Japan), and assigned an accession number of FERM BP-11091.
Since the nucleotide sequence of the cysJ gene may differ depending on the genus, species or strain to which the bacterium belongs, the cysJ gene of which expression is increased may be a variant of the nucleotide sequence shown as SEQ ID NO: 39 or 41, so long as it codes for a protein having the sulfite-reducing activity. A variant of the cysJ gene can be searched for by using BLAST (blast.genome.jp/) or the like with referring to, for example, the nucleotide sequence of SEQ ID NO: 39 or 41. The variant of the cysJ gene can include homologues of the gene, such as genes that can be amplified by PCR using a chromosome of such a microorganism as bacteria belonging to the family Enterobacteriaceae and coryneform bacteria as a template and synthetic oligonucleotides prepared on the basis of the nucleotide sequence of SEQ ID NO: 39 or 41.
The cysJ gene may encode for a protein having the amino acid sequence of the CysJ protein as mentioned above, such as the amino acid sequence shown as SEQ ID NO: 40 or 42, but can also include substitution, deletion, insertion, addition or the like of one or several amino acid residues at one or several positions, so long as it codes for a protein having the sulfite-reducing activity. Although the number meant by the term “one or several” may differ depending on positions in the three-dimensional structure of the protein or types of amino acid residues, specifically, it can be 1 to 20, 1 to 10, or even 1 to 5. The above substitution, deletion, insertion, or addition of one or several amino acid residues can be a conservative mutation that maintains normal function of the protein. The conservative mutation is typically a conservative substitution. The conservative substitution is a mutation wherein substitution takes place mutually among Phe, Trp and Tyr, if the substitution site is an aromatic amino acid; among Leu, Ile and Val, if it is a hydrophobic amino acid; between Gln and Asn, if it is a polar amino acid; among Lys, Arg and His, if it is a basic amino acid; between Asp and Glu, if it is an acidic amino acid; and between Ser and Thr, if it is an amino acid having hydroxyl group. Specific examples of conservative substitutions include: substitution of Ser or Thr for Ala; substitution of Gln, His or Lys for Arg; substitution of Glu, Gln, Lys, His or Asp for Asn; substitution of Asn, Glu or Gln for Asp; substitution of Ser or Ala for Cys; substitution of Asn, Glu, Lys, His, Asp or Arg for Gln; substitution of Gly, Asn, Gln, Lys or Asp for Glu; substitution of Pro for Gly; substitution of Asn, Lys, Gln, Arg or Tyr for His; substitution of Leu, Met, Val or Phe for Ile; substitution of Ile, Met, Val or Phe for Leu; substitution of Asn, Glu, Gln, His or Arg for Lys; substitution of Ile, Leu, Val or Phe for Met; substitution of Trp, Tyr, Met, Ile or Leu for Phe; substitution of Thr or Ala for Ser; substitution of Ser or Ala for Thr; substitution of Phe or Tyr for Trp; substitution of His, Phe or Trp for Tyr; and substitution of Met, Ile or Leu for Val. The above-mentioned amino acid substitution, deletion, insertion, addition, inversion etc. can be a result of a naturally-occurring mutation (mutant or variant) due to an individual difference, a difference of species, or the like of a bacterium from which the gene is derived.
Furthermore, the gene having such a conservative mutation as mentioned above may be a gene coding for a protein showing a homology of 80% or more, 90% or more, 95% or more, 97% or more, or even 99% or more, to the total amino acid sequence of the CysJ protein, such as the total sequence of the amino acid sequence of SEQ ID NO: 40 or 42, and having the sulfite-reducing activity. In this specification, “homology” may mean “identity”.
The cysJ gene may be a DNA that is able to hybridize with a probe that can be prepared from a known gene sequence, for example, a sequence complementary to a part or all of the nucleotide sequence of SEQ ID NO: 39 or 41, under stringent conditions, and coding for a protein having the sulfite-reducing activity. The “stringent conditions” can refer to conditions under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed. Examples of the stringent conditions include those under which highly homologous DNAs hybridize to each other, for example, DNAs not less than 80% homologous, not less than 90% homologous, not less than 95% homologous, not less than 97% homologous, or even not less than 99% homologous, hybridize to each other, and DNAs less homologous than the above do not hybridize to each other, or conditions of washing of typical Southern hybridization, i.e., conditions of washing once, or 2 or 3 times, at a salt concentration and temperature corresponding to 1×SSC, 0.1% SDS at 60° C.; 0.1×SSC, 0.1% SDS at 60° C.; or 0.1×SSC, 0.1% SDS at 68° C.
The probe used for the aforementioned hybridization may be a sequence that is complementary to a part of the gene as described above. Such a probe can be prepared by PCR using oligonucleotides prepared on the basis of a known gene sequence as primers and a DNA fragment containing the nucleotide sequence as a template. For example, when a DNA fragment having a length of about 300 bp is used as the probe, the washing conditions of the hybridization may be, for example, 50° C., 2×SSC and 0.1% SDS.
Similarly, since the nucleotide sequence of the cysI gene may differ depending on the genus, species or strain to which the bacterium belongs, the cysI gene of which expression is increased may be a variant of the nucleotide sequence of SEQ ID NO: 43 or 45, so long as it codes for a protein having the sulfite-reducing activity. The above explanations for variants of the cysJ gene and CysJ protein are similarly applied to the above variant of the cysI gene.
Similarly, since the nucleotide sequence of the cysG gene may differ depending on the genus, species or strain to which the bacterium belongs, the cysG gene of which expression is increased may be a variant of the nucleotide sequence of SEQ ID NO: 47 or 49, so long as it codes for a protein having the activity of catalyzing conversion of uroporphyrinogen III (Uro′gen III) into siroheme. The above explanation for variants of the cysJ gene and CysJ protein is similarly applied to the above variant of the cysG gene.
The aforementioned explanation of the variants of genes and proteins are also similarly applied to arbitrary proteins including enzymes such as serine acetyltransferase and 3-phosphoglycerate dehydrogenase and transporters such as YdeD protein, and the genes coding for them.
The phrase “expression of a gene involved in sulfite reduction is increased” can mean that the expression amount of the gene involved in sulfite reduction is increased compared with that of a non-modified strain such as a wild-type strain or a parent strain. Although the degree of increase of expression amount of the gene involved in sulfite reduction is not particularly limited so long as it is increased compared with that of a non-modified strain, it can be increased 1.5 times or more, 2 times or more, 3 times or more, compared with that of a non-modified strain. The phrase “expression of a gene involved in sulfite reduction is increased” can include not only when expression of a gene involved in sulfite reduction is increased in a strain in which the gene involved in sulfite reduction is natively expressed, but also when a gene involved in sulfite reduction is expressed in a strain in which the gene involved in sulfite reduction has not been natively expressed. That is, for example, when a gene involved in sulfite reduction is introduced into a strain not having the gene involved in sulfite reduction, and the gene involved in sulfite reduction is expressed in the strain. Moreover, so long as expression of a gene involved in sulfite reduction is increased as a result, expression of a gene involved in sulfite reduction and natively possessed by a bacterium may be attenuated or deleted, and then an appropriate sulfite reductase may be introduced.
The bacterium can be modified so that expression of at least a gene coding for siroheme synthetase is increased. Furthermore, the bacterium can be modified so that expression of a gene coding for siroheme synthetase is increased, and expression of a gene coding for sulfite reductase is increased.
Modification for increasing expression of a gene involved in sulfite reduction can be attained by the methods for enhancing expression of a gene exemplified in the section of <Methods for increasing enzymatic activity> mentioned above.
In addition, as mentioned above, a modification for increasing expression of a gene may also be attained by amplifying a regulator that increases expression of the objective gene. Examples of a regulator that increases expression of a gene coding for a sulfite reductase include the protein (CysB) encoded by the cysB gene. It is known that CysB positively regulates expression of the cysJIH operon containing the cysJ gene and cysI gene coding for a sulfite reductase, and therefore expression of a gene involved in sulfite reduction can be enhanced by enhancing expression of the cysB gene.
Increase of the expression of a gene can be confirmed by, for example, confirming the increase of the transcription amount of the gene by Northern hybridization or RT-PCR as described above, or by confirming increase of the protein amount by Western blotting. Furthermore, increase of the expression of a gene involved in sulfite reduction can also be confirmed by measuring activity of the protein encoded by the gene involved in sulfite reduction. Activity of sulfite reductase can be measured by a known method (Covbs J. et al., J. Biol. Chem., 268, 18604-18609 (1993)). Activity of siroheme synthetase can also be measured by a known method (Spencer J. B. et al., FEBS Lett., 335(1):57-60, Nov. 29, 1993).
<2> Method for Producing L-Cysteine, Related Substance Thereof or Mixture Thereof
By culturing the bacterium described herein, obtained as described above, in a medium containing thiosulfate and collecting L-cysteine, a related substance thereof or a mixture thereof from the medium, these compounds can be produced. Examples of the related substance of L-cysteine include L-cystine, S-sulfocysteine, thiazolidine derivatives, hemithioketals corresponding to the thiazolidine derivatives, L-methionine, S-adenosylmethionine, and so forth mentioned above.
The medium can be any ordinary media which includes a carbon source, nitrogen source, sulfur source, inorganic ions, and other organic components as required, and must include thiosulfate.
As the nitrogen source, inorganic ammonium salts such as ammonium sulfate, ammonium chloride and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, aqueous ammonia and so forth can be used.
As the sulfur source, thiosulfate alone may be included, or other sulfur compounds may be also be present in the medium in addition to thiosulfate. Examples of other sulfur compounds include inorganic sulfur compounds such as sulfates, sulfites, hyposulfites and sulfides. Although the weight ratio of thiosulfate and the other sulfur compound contained in the medium is not particularly limited, for example, the weight ratio of thiosulfate:other sulfur source is usually 5:95 to 100:0, 20:80 to 100:0, 50:50 to 100:0, or even 80:20 to 100:0.
The content of thiosulfate in the medium can be, for example, usually 0.1 g/L or higher, or 0.3 g/L or higher. Although the maximum content of thiosulfate is not particularly limited, it may be, for example, 100 g/L or lower, or 10 g/L or lower. Thiosulfate may be a free acid or thiosulfate salt, or may be an arbitrary mixture thereof. The type of thiosulfate salt is not particularly limited, and examples include sodium salt, calcium salt, ammonium salt, and so forth.
Thiosulfate may be present in the medium over the entire period of the culture, or only a part of the culture period. For example, if the method includes a proliferation stage of the L-cysteine-producing bacterium, and a L-cysteine producing stage, it is sufficient that thiosulfate is present during at least the production stage, and thiosulfate may be or may not be present in the medium during the proliferation stage. Furthermore, thiosulfate may be present in the medium over the entire period or only a part of the L-cysteine producing stage. For example, the thiosulfate amount does not need to be within the aforementioned range over the entire period of the production stage, that is, thiosulfate may be present in the medium within the aforementioned range during an early period of that stage, and the thiosulfate content may decrease with the lapse of the culture time. Furthermore, thiosulfate may be added continuously or intermittently. In addition, the contents of medium components other than thiosulfate may also vary during the culture period, and they may be added during the culture period.
As organic trace amount nutrients, required substances such as vitamin B1, yeast extract and so forth can be added in appropriate amounts. Other than these, potassium phosphate, magnesium sulfate, iron ions, manganese ions and so forth can be added in small amounts, as required.
The culture can be performed under aerobic conditions for 30 to 90 hours. The culture temperature can be controlled to be at 25° C. to 37° C., and pH can be controlled to be 5 to 8 during the culture. To adjust the pH, inorganic or organic acidic or alkaline substances, ammonia gas and so forth can be used.
L-cysteine, a related substance thereof or a mixture thereof can be collected from the culture broth by a combination of ion-exchange resin method (Nagai, H. et al., Separation Science and Technology, 39(16), 3691-3710), membrane separation method (Japanese Patent Laid-open (Kokai) Nos. 9-164323 and 9-173792), crystallization method (WO2008/078448, WO2008/078646), and other conventionally known methods.
The collected L-cysteine, a related substance thereof or a mixture thereof can contain microbial cells, medium components, moisture, metabolic by-products of microbes, and so forth in addition to the objective compounds.
L-cysteine obtained as described above can be used for production of L-cysteine derivatives. The L-cysteine derivatives include methylcysteine, ethylcysteine, carbocisteine, sulfocysteine, acetylcysteine, and so forth.
Furthermore, when a thiazolidine derivative of L-cysteine is accumulated in the medium, L-cysteine can be produced by collecting the thiazolidine derivative from the medium and breaking the reaction equilibrium between the thiazolidine derivative and L-cysteine so that L-cysteine is excessively produced. When S-sulfocysteine is accumulated in the medium, it can be converted into L-cysteine by reduction using a reducing agent such as dithiothreitol.
Hereafter, the present invention will be explained more specifically with reference to the following non-limiting example. In the following example, cysteine means L-cysteine.
Example Production of Cysteine by E. Coli Overexpressing cysG Gene or cysGJI Genes Using Thiosulfate as the Sulfur Source Construction of Expression Plasmids for Genes Involved in Sulfite Reduction
As genes involved in sulfite reduction, the cysG gene of P. ananatis SC17 strain, the cysGJI genes of P. ananatis SC17 strain, the cysG gene of E. coli MG1655 strain, and the cysGJI genes of E. coli MG1655 strain were used. These genes were each cloned in an expression vector to construct expression plasmids of the genes. The procedure is described in (1-1) to (1-7).
As the expression vector, pMIV-Pnlp23-ter constructed from pMIV-5JS (Japanese Patent Laid-open (Kokai) No. 2008-99668) was used. This vector has the nlp23 promoter (Pnlp23), which is a strong promoter, and the rrnB terminator, and has SalI and XbaI sites between Pnlp23 and the rrnB terminator. By amplifying an objective gene using primers in which SalI (or XhoI) and XbaI sites are designed, and inserting the amplified gene into the vector at a position between Pnlp23 and the rrnB terminator, an expression plasmid of the objective gene can be constructed. “Pnlp23” is a mutant promoter constructed from “Pnlp0”, which is a promoter of the wild-type nlpD gene derived from the E. coli K12 strain, in order to control expression intensity.
As the expression vector, pMIV-Pnlp8-YeaS7 constructed from pMIV-5JS (Japanese Patent Laid-open (Kokai) No. 2008-99668) was also used. This vector has the nlp8 promoter (Pnlp8), which is a strong promoter, and the rrnB terminator, and further has the yeaS gene of the E. coli K12 strain cloned at a position between Pnlp8 and the rrnB terminator using SalI and XbaI sites. By amplifying an objective gene using primers in which SalI (or XhoI) and XbaI sites are designed, and inserting the amplified gene into the vector, an expression plasmid in which the yeaS gene fragment of the vector is replaced with the objective gene fragment can be constructed. “Pnlp8” is a mutant promoter constructed from “Pnlp0”, which is a promoter of the wild-type nlpD gene of the E. coli K12 strain, in order to control expression intensity.
The details of the construction of these expression vectors are described below.
First, by PCR using the chromosomal DNA of the E. coli MG1655 strain as the template as well as a primer P1 (agctgagtcgacccccagga aaaattggttaataac, SEQ ID NO: 13) and a primer P2 (agctgagcatgcttccaactgcgctaatgacgc, SEQ ID NO: 14) as primers, a DNA fragment containing a promoter region of the nlpD gene (henceforth wild-type nlpD gene promoter is referred to as “Pnlp0”) of about 300 bp was obtained. At the 5′ ends of the aforementioned primers, sites for the restriction enzymes SalI and PaeI were designed, respectively. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 25 cycles of 94° C. for 20 seconds, 55° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes. The resulting fragment was treated with SalI and PaeI, and inserted into pMIV-5JS (Japanese Patent Laid-open (Kokai) No. 2008-99668) at the SalI-PaeI site to obtain the plasmid pMIV-Pnlp0. The nucleotide sequence of the PaeI-SalI fragment containing the Pnlp0 promoter inserted into this pMIV-Pnlp0 plasmid was as shown in SEQ ID NO: 1.
Then, by PCR using the chromosomal DNA of the MG1655 strain as the template, as well as primer P3 (agctgatcta gaaaacagaa tttgcctggc ggc, SEQ ID NO: 15) and primer P4 (agctgaggat ccaggaagag tttgtagaaa cgc, SEQ ID NO: 16) as primers, a DNA fragment containing a terminator region of the rrnB gene of about 300 bp was obtained. At the 5′ ends of the aforementioned primers, sites for the restriction enzymes XbaI and BamHI were designed, respectively. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 25 cycles of 94° C. for 20 seconds, 59° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes. The obtained fragment was treated with XbaI and BamHI, and inserted into pMIV-Pnlp0 at the XbaI-BamHI site to obtain the plasmid pMIV-Pnlp0-ter.
Then, by PCR using the chromosomal DNA of the MG1655 strain as the template, as well as primer P5 (agctgagtcg acgtgttcgc tgaatacggg gt, SEQ ID NO: 17) and primer P6 (agctgatcta gagaaagcat caggattgca gc, SEQ ID NO: 18) as primers, a DNA fragment of about 700 bp containing the yeaS gene was obtained. At the 5′ ends of the aforementioned primers, sites for the restriction enzymes SalI and XbaI were designed, respectively. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 25 cycles of 94° C. for 20 seconds, 55° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes. The resulting fragment was treated with SalI and XbaI, and inserted into pMIV-Pnlp0-ter at the SalI-XbaI site to obtain the plasmid pMIV-Pnlp0-YeaS3. As described above, a yeaS expression unit including the nlpD promoter, the yeaS gene, and the rrnB terminator ligated in this order was constructed on the pMIV-5JS vector.
In order to modify the −10 region of the nlpD promoter to make it a stronger promoter, the −10 region was randomized by the following method. The nlpD promoter region contains two of regions presumed to function as promoters (FIG. 2), and they are indicated as pnlp1 and pnlp2, respectively, in the drawing. By PCR using the plasmid pMIV-Pnlp0 as the template as well as the primers P1 and P7 (atcgtgaaga tcttttccag tgttnannag ggtgccttgc acggtnatna ngtcactgg (“n” means that the corresponding residue can be any of a, t, g and c), SEQ ID NO: 19) as primers, a DNA fragment in which the −10 region located at the 3′ end side of the nlpD promoter (−10(Pnlp1), FIG. 2) was randomized was obtained. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 25 cycles of 94° C. for 20 seconds, 60° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes.
Similarly, by PCR using the plasmid pMIV-Pnlp0 as the template as well as the primers P2 and P8 (tggaaaagat cttcannnnn cgctgacctg cg (“n” means that the corresponding residue can be any of a, t, g and c), SEQ ID NO: 20) as primers, a DNA fragment in which the −10 region located at the 5′ end side of the nlpD promoter (−10(Pnlp2), FIG. 2) was randomized was obtained. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 25 cycles of 94° C. for 20 seconds, 60° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes.
The obtained 3′ and 5′ end side fragments were ligated by using the BglII sites designed in the primers P7 and P8 to construct a fragment containing the full length of the nlpD promoter in which two −10 regions were randomized. By PCR using this fragment as the template as well as the primers P1 and P2 as primers, a DNA fragment containing the full length of a mutant type nlpD promoter was obtained. The PCR cycle was as follows: 95° C. for 3 minutes, followed by 2 cycles of 95° C. for 60 seconds, 50° C. for 30 seconds, and 72° C. for 40 seconds, 12 cycles of 94° C. for 20 seconds, 60° C. for 20 seconds, and 72° C. for 15 seconds, and a final cycle of 72° C. for 5 minutes.
The obtained DNA fragment containing the mutant Pnlp was treated with the restriction enzymes SalI and PaeI, for which sites were designed in the 5′ ends of the primers, and inserted into the plasmid pMIV-Pnlp0-YeaS3 similarly treated with SalI and PaeI to substitute the mutant Pnlp for the wild-type nlpD promoter region (Pnlp0) on the plasmid. From the resultants, one having the promoter sequence (Pnlp8) shown in FIG. 2 was selected, and designated pMIV-Pnlp8-YeaS7. The nucleotide sequence of the PaeI-SalI fragment of the Pnlp8 promoter inserted into this plasmid was as shown in SEQ ID NO: 21.
In the same manner, a DNA fragment containing the mutant Pnlp was inserted into the plasmid pMIV-Pnlp0-ter treated with SalI and PaeI to substitute the mutant Pnlp for the nlpD promoter region (region of Pnlp0) on the plasmid. One of the resultants was designated pMIV-Pnlp23-ter. The nucleotide sequence of the PaeI-SalI fragment of the Pnlp23 promoter inserted into this plasmid was as shown in SEQ ID NO: 2.
(1-2) Construction of Overexpression Plasmid for cysG Gene of E. Coli MG1655 Strain
By PCR using the chromosomal DNA of the E. coli MG1655 strain (ATCC No. 47076) as the template, as well as primer SalI-cysG (Ec) Fw (ACGCGTCGACATGGATCATTTGCCTATATT, SEQ ID NO: 8) and primer XbaI-cysG (Ec) Rv (GCTCTAGATTAATGGTTGGAGAACCAGTTC, SEQ ID NO: 9) as primers, the cysG gene fragment was amplified. At the 5′ ends of these primers, sites for the restriction enzymes SalI and XbaI were designed. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle of 94° C. for 5 minutes, followed by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. The obtained fragment was treated with SalI and XbaI, and inserted into pMIV-Pnlp23-ter treated with the same restriction enzymes to obtain the plasmid pMIV-Pnlp23-cysG (Ec) in which the cysG gene of the E. coli MG1655 strain was cloned.
(1-3) Cloning of cysJI Genes of E. Coli MG1655 Strain
By PCR using the chromosomal DNA of the E. coli MG1655 strain as the template as well as primer SalI-cysJ (Ec) Fw (ACGCGTCGACATGACGACACAGGTCCCACC, SEQ ID NO: 10) and primer XbaI-cysI (Ec) Rv (GCTCTAGATTAATCCCACAAATCACGCGCC, SEQ ID NO: 11), the cysJI gene fragment was amplified. At the 5′ ends of these primers, sites for the restriction enzymes SalI and XbaI were designed. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle consisting of 94° C. for 5 minutes, followed by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. The obtained fragment was treated with SalI and XbaI, and inserted into pMIV-Pnlp23-ter treated with the same restriction enzymes to obtain the plasmid pMIV-Pnlp23-cysJI (Ec) in which the cysJI genes of the E. coli MG1655 strain were cloned.
(1-4) Construction of Coexpression Plasmid for cysG Gene and cysJI Genes of E. coli MG1655 Strain
PCR was performed by using the chromosomal DNA of the E. coli MG1655 strain as the template as well as the primer SalI-cysG (Ec) Fw (SEQ ID NO: 8) and primer cysG-JI (Ec) Rv (CAACGCGGAAGGTGGGACCTGTGTCGTCATGCGTCGTTATGTTCCAGTTTAATGGTT GGAGAACCAGTTCAGTTTATC, SEQ ID NO: 12) as primers. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle consisting of 94° C. for 5 minutes, follow by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. By this PCR, a gene fragment which includes the cysG gene and a sequence of 18 bp containing the start codon of the cysJ gene added downstream of the cysG gene was obtained. The salts, polymerase, and primers were removed from the reaction mixture containing the obtained fragment, and the resultant was used as a primer of the following PCR.
PCR was performed by using the plasmid DNA of pMIV-Pnlp23-cysJI (Ec) constructed in (1-3) as a template, as well as the aforementioned gene fragment and the primer XbaI-cysI (Ec) Rv (SEQ ID NO: 11) as primers. PCR was performed by using PrimeSTAR GXL Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle consisting of 98° C. for 10 seconds, followed by 30 cycles of 98° C. for 10 seconds, 58° C. for 15 seconds, and 68° C. for 2 minutes, and keeping at 4° C. as the final cycle. By this PCR, a gene fragment which includes the cysG gene sequence and the cysJI gene sequence ligated downstream of the cysG gene sequence was obtained. At the 5′ ends of the primers, SalI and XbaI sites were designed, respectively. The obtained fragment was treated with SalI and XbaI, and inserted into pMIV-Pnlp23-ter treated with the same restriction enzymes to obtain the plasmid pMIV-Pnlp23-cysGJI (Ec) in which the cysGJI genes of the E. coli MG1655 strain were cloned.
(1-5) Construction of Overexpression Plasmid for cysG Gene of P. ananatis SC17 Strain
By PCR using the chromosomal DNA of the P. ananatis SC17 strain (FERM BP-11091) as the template, as well as primer CysG Fw (XhoI) (ACGCCTCGAGATGGATTATTTGCCTCTTTT, SEQ ID NO: 3) and primer CysG Rv (XbaI) (GCTCTAGATCAAGCCAGATTGACAACGG, SEQ ID NO: 4) as primers, the cysG gene fragment was amplified. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle of 94° C. for 5 minutes, follow by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. Although the start codon of the cysG gene on the chromosomal DNA of P. ananatis was GTG, the start codon of the cysG gene present in the DNA fragment obtained by PCR was modified to ATG by changing GTG in the sequence of the start codon attaching site of the primer to ATG. Further, at the 5′ ends of the aforementioned primers, XhoI and XbaI sites were designed, respectively. Because a restriction enzyme site for SalI existed in the ORF of the cysG gene of P. ananatis, XhoI was used as a substitute for SalI. The obtained fragment was treated with XhoI and XbaI, and inserted into pMIV-Pnlp8-YeaS7 treated with SalI and XbaI to obtain the plasmid pMIV-Pnlp8-cysG (Pa) in which the cysG gene of the P. ananatis SC17 strain was cloned. pMIV-Pnlp8-cysG (Pa) has a structure that the yeaS gene fragment on pMIV-Pnlp8-YeaS7 was replaced with the cysG gene fragment of the P. ananatis SC17 strain.
(1-6) Cloning of cysJI Genes of P. ananatis SC17 Strain
By PCR using the chromosomal DNA of the P. ananatis SC17 strain as the template, as well as primer CysJ Fw (SalI) (ACGCGTCGACATGACGACTCAGGCACCAGG, SEQ ID NO: 5) and primer CysI Rv (XbaI) (GCTCTAGATCATTTTGCCTCCTGCCAGA, SEQ ID NO: 6) as primers, the cysJI gene fragment was amplified. At the 5′ ends of the aforementioned primers, sites for the restriction enzymes SalI and XbaI were designed, respectively. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle consisting of 94° C. for 5 minutes, followed by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. The obtained fragment was treated with SalI and XbaI, and inserted into pMIV-Pnlp23-ter treated with the same restriction enzymes to obtain the plasmid pMIV-Pnlp23-cysJI (Pa) in which the cysJI genes of the P. ananatis SC17 strain were cloned.
(1-7) Construction of Coexpression Plasmid for cysG Gene and cysJI Genes of P. ananatis SC17 Strain
PCR was performed by using the chromosomal DNA of the P. ananatis SC17 strain as the template as well as the primer CysG Fw (XhoI) (SEQ ID NO: 3) and primer CysG-JI Rv (CTGGTGCCTGAGTCGTCATCGTTTTTCCTCTCAAGCCAGATTGACAACGGCGGACTC GCG, SEQ ID NO: 7) as primers. PCR was performed by using PrimeSTAR Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle of 94° C. for 5 minutes, followed by 30 cycles of 98° C. for 5 seconds, 55° C. for 10 seconds, and 72° C. for 2 minutes, and keeping at 4° C. as the final cycle. By this PCR, a gene fragment which includes the cysG gene and a sequence of 11 bp containing the start codon of the cysJ gene added downstream of the cysG gene was obtained. The salts, polymerase, and primers were removed from the reaction mixture containing the obtained fragment, and the resultant was used as a primer for the following PCR.
PCR was performed by using the plasmid DNA of pMIV-Pnlp23-cysJI (Pa) constructed in (1-6) as the template, as well as the aforementioned gene fragment and the primer CysI Rv (XbaI) (SEQ ID NO: 6) as primers. PCR was performed by using PrimeSTAR GXL Polymerase (TaKaRa) and a standard reaction mixture composition described in the attached protocol with a PCR cycle of 98° C. for 10 seconds, followed by 30 cycles of 98° C. for 10 seconds, 58° C. for 15 seconds, and 68° C. for 2 minutes, and keeping at 4° C. as the final cycle. By this PCR, a gene fragment which includes the cysG gene sequence and the cysJI gene sequence ligated downstream of the cysG gene sequence was obtained. Although the start codon of the cysG gene on the chromosomal DNA of P. ananatis was GTG, the start codon of the cysG gene contained in the DNA fragment obtained by PCR was modified to ATG by changing GTG in the sequence of the start codon attaching site of the primer to ATG. Furthermore, at the 5′ ends of the primers, XhoI and XbaI sites were designed, respectively. Since a restriction enzyme site for SalI existed in the ORF of the cysG gene of P. ananatis, XhoI was used as a substitute for SalI. The obtained fragment was treated with XhoI and XbaI, and inserted into pMIV-Pnlp23-ter treated with SalI and XbaI to obtain the plasmid pMIV-Pnlp23-cysGJI (Pa) in which the cysGJI genes of the P. ananatis SC17 strain were cloned.
(2) Construction of Cysteine-Producing E. Coli Bacterium
As a cysteine-producing E. coli bacterium, the MG1655int-4M/pACYC-DES strain was constructed which harbors the plasmid pACYC-DES having the ydeD gene, cysEX gene and serA5 gene, in which strain the cysM gene was introduced into the chromosome. The construction procedure will be described in (2-1) and (2-2).
(2-1) Construction of Plasmid pACYC-DES Having ydeD Gene, cysEX Gene and serA5 Gene
The ydeD gene, cysEX gene and serA5 gene were cloned into the plasmid pACYC184 to construct the plasmid pACYC-DES. The ydeD gene encodes a transmembrane protein involved in secretion of metabolic products of the cysteine pathway, and it has been reported that it is useful for the cysteine production (U.S. Pat. No. 5,972,663). The cysEX gene is a mutant gene of cysE and codes for a mutant serine acetyltransferase (SAT) desensitized to feedback inhibition by cysteine (U.S. Pat. No. 6,218,168). The serA5 gene is a mutant gene of serA and codes for a mutant 3-phosphoglycerate dehydrogenase (PGD) deficient in the tyrosine residue at the C-terminus of the wild-type 3-phosphoglycerate dehydrogenase of Escherichia coli and desensitized to feedback inhibition by L-serine (U.S. Pat. No. 6,180,373). The construction procedure is shown below.
By PCR using the chromosomal DNA of the E. coli MG1655 strain as the template, as well as primer ydeD299F (agctgagtcg acatgtcgcg aaaagatggg gtg, SEQ ID NO: 22) and primer ydeD299R (agctgatcta gagtttgttc tggccccgac atc, SEQ ID NO: 23) as primers, the ydeD gene fragment of the Escherichia coli MG1655 strain was amplified.
Furthermore, as shown in FIG. 3, the cysEX gene fragment was prepared. Specifically, first, by PCR using the chromosomal DNA of the E. coli MG1655 strain as the template, as well as primer cysEF (agctgagtcg acatgtcgtg tgaagaactg gaa, SEQ ID NO: 24) and primer cysEX-1 (atcaccgccg cttcaccaac g, SEQ ID NO: 25) as primers, an upstream side fragment of the cysEX gene was amplified. Then, by PCR using the chromosomal DNA of the E. coli MG1655 strain as the template, as well as primer cysEX-2 (cgttggtgaa gcggcggtga t, SEQ ID NO: 26) and primer cysER (agctgatcta gaatagatga ttacatcgca tcc, SEQ ID NO: 27) as primers, a downstream side fragment of the cysEX gene was amplified. These two PCR products were separated by electrophoresis and eluted from the gel. Subsequently, by performing PCR again using these two PCR products, these two PCR products were annealed at the overlapping portions to generate a DNA fragment containing the full length of the cysEX gene.
Furthermore, by PCR using the chromosomal DNA of the E. coli MG1655 strain as the template, as well as primer serA5F (agctgagtcg acatggcaaa ggtatcgctg gag, SEQ ID NO: 28) and primer serA5R (agctgatcta gattacagca gacgggcgcg aatgg, SEQ ID NO: 29) as primers, a serA5 gene fragment was amplified.
Furthermore, by PCR using the chromosomal DNA of the E. coli MG1655 strain as the template, as well as primer PrOMPAF (agctgagtcg accgcctcgt tatcatccaa aatc, SEQ ID NO: 30) and primer PrOMPAR (agctgagcat gcactaattt tccttgcgga ggc, SEQ ID NO: 31) as primers, a promoter PompA fragment was amplified.
At the 5′ ends of the primer PrOMPAF, the primers ydeD299F, cysEF and serA5F for gene fragment amplification, SalI sites were designed. The amplified PompA fragment and each amplified gene fragment were treated with SalI and ligated to obtain three kinds of DNA fragments which include PompA and each gene ligated downstream of PompA.
Furthermore, at the 5′ end of the primer PrOMPAR, a PaeI site was designed. At the 5′ ends of the primers ydeD299R, cysER and serA5R for gene fragment amplification, restriction enzyme sites for incorporation into a vector were designed. By using these restriction enzyme sites, the three kinds of DNA fragments which include PompA and each gene ligated downstream of PompA were introduced into the plasmid pACYC184. A plasmid obtained as described above was designated pACYC-DES. The structure of pACYC-DES is shown in FIG. 4.
(2-2) Introduction of O-Acetyl-L-Serine Sulfhydrylase B Gene (cysM) into E. coli MG1655 Strain
The O-acetyl-L-serine sulfhydrylase B gene (cysM) was introduced into the chromosome of the E. coli MG1655 strain to construct the MG1655int-4M strain. Furthermore, the plasmid pACYC-DES was introduced into the MG1655int-4M strain to construct an MG1655int-4M/pACYC-DES strain. For expression of the cysM gene introduced into the E. coli MG1655 strain, the promoter of the wild-type nlpD gene of the P. ananatis SC17 strain, “Pnlp4”, was used. The construction procedure is explained below.
First, in order to express the cysM gene by using a promoter of an appropriate strength, a novel promoter Pnlp4 was obtained by the following procedure.
First, a DNA fragment containing about 180 bp of the promoter region of the nlpD gene was obtained by PCR using the genome of the P. ananatis SC17 strain as the template. The promoter of the wild-type nlpD gene of the P. ananatis SC17 strain amplified as described above is referred to as “Pnlp4”. The primers used were primer P9 (agctgaaagc ttgcatgcac gcgtggcgat ctggcctgac tgc, SEQ ID NO: 32) and primer P10 (agctgagtcg accccgtggt ggcaaccttt aaaaaactg, SEQ ID NO: 33), and at the 5′ ends of these primers, sites for the restriction enzymes SalI and PaeI were designed, respectively. The PCR cycle was as follows: 95° C. for 5 minutes, follow by 27 cycles of 94° C. for 20 seconds, 59° C. for 20 seconds, and 72° C. for 20 seconds, and a final cycle of 72° C. for 5 minutes. The obtained DNA fragment was treated with SalI and PaeI, and inserted into pMIV-Pnlp0-ter similarly treated with SalI and PaeI to obtain the plasmid pMIV-Pnlp-4-ter, which corresponded to pMIV-Pnlp0-ter in which Pnlp0 was replaced with Pnlp4. The nucleotide sequence of the PaeI-SalI fragment of Pnlp4 inserted into pMIV-Pnlp-4-ter is as shown in SEQ ID NO: 34.
The cysM gene cloned from the E. coli MG1655 strain was incorporated into the plasmid pMIV-Pnlp-4-ter obtained in (2-2). Specifically, by PCR using the genome of the E. coli MG1655 strain as the template, as well as primer P11 (agctgagtcg acgtgagtacattagaacaa acaat, SEQ ID NO: 37) and primer P12 (agctgatcta gaagtctccg atgctattaa tcc, SEQ ID NO: 38) as primers (98° C. for 5 minutes, followed by 30 cycles of 98° C. for 5 seconds, 50° C. for 10 seconds, and 72° C. for 60 seconds, and a final cycle of 72° C. for 2 minutes), the cysM gene fragment was amplified. The DNA fragment obtained as described above was treated with SalI and XbaI, and inserted into pMIV-Pnlp-4-ter treated with the same enzymes to prepare the plasmid pMIV-Pnlp-4-CysM, in which the cysM gene of the E. coli MG1655 strain was cloned. The nucleotide sequence of the cysM gene of the E. coli MG1655 strain is shown as SEQ ID NO: 35, and the amino acid sequence encoded by this gene is shown as SEQ ID NO: 36.
pMIV-Pnlp-4-CysM has the attachment sites for Mu phage originated from pMIV-5JS. Therefore, by allowing pMIV-Pnlp-4-CysM to coexist with the helper plasmid pMH10 having the Mu transposase gene (Zimenkov D. et al., Biotechnologiya (in Russian), 6, 1-22 (2004)) in a host cell, the cassette of Pnlp-4-CysM-rrnB terminator containing the chloramphenicol resistance gene existing on pMIV-Pnlp-4-CysM between the attachment sites of Mu phage can be inserted into the chromosome of the host. Furthermore, the chloramphenicol resistance gene carried by the pMIV-Pnlp-4-CysM plasmid exists between two attachment sites of λ phage (λattR and λattL), and can be excised and removed by the method described later.
First, the helper plasmid pMH10 was introduced into the MG1655 strain by electroporation, and the strain was cultured overnight at 30° C. on the LB agar medium containing 20 mg/L of kanamycin to select a strain into which pMH10 was introduced. The obtained transformant was cultured at 30° C., and pMIV-Pnlp-4-CysM was further introduced into this strain by electroporation. This strain, which was transformed with both pMH10 and pMIV-Pnlp-4-CysM, was subjected to a heat shock at 42° C. for 20 minutes, and then cultured at 39° C. on LB agar medium containing 20 mg/L of chloramphenicol to select colonies of chloramphenicol resistant strains. About 50 clones of the chloramphenicol resistant strains obtained as described above were each cultured at 39° C. for 48 hours on LB agar medium to eliminate pMH10 and pMIV-Pnlp-4-CysM. Then, a strain was obtained showing chloramphenicol resistance as a result of the insertion of the cassette containing the chloramphenicol resistance gene into the chromosome and showing kanamycin and ampicillin sensitivities as a result of the elimination of the both plasmids. Furthermore, it was confirmed that the objective cassette was inserted into the chromosome of the obtained strain by PCR using the chromosomal DNA of this strain as the template as well as the primers P1 and P6. The strain prepared as described above was designated MG1655int-4M (CmR).
The chloramphenicol resistance gene introduced into the MG1655int-4M (CmR) strain was removed with an excision system derived from λ phage. Specifically, the MG1655int-4M (CmR) strain was transformed with pMT-Int-Xis2 (WO2005/010175) carrying the Int-Xis gene of λ phage, and the MG1655int-4M strain showing chloramphenicol sensitivity was obtained from the obtained transformants.
Then, the plasmid pACYC-DES was introduced into MG1655int-4M to obtain the MG1655int-4M/pACYC-DES strain.
(3) Cysteine Production by E. Coli Overexpressing cysG Gene or cysGJI Genes using Thiosulfate as a Sulfur Source
Strains of the above-obtained E. coli cysteine-producing bacterium, MG1655int-4M/pACYC-DES, were constructed, and into which the cysG overexpression plasimids pMIV-Pnlp23-cysG (Ec) and pMIV-Pnlp8-cysG (Pa), the cysG and cysJI coexpression plasmids pMIV-Pnlp23-cysGJI (Ec) and pMIV-Pnlp23-cysGJI (Pa), and pMIV-5JS as a control were each introduced. Cysteine production culture was performed with these strains, and cysteine production amounts were compared. For the cysteine production culture, a cysteine production medium having the following composition containing glucose as a carbon source and thiosulfate as a sulfur source was used.
Cysteine Production Medium: (Concentrations of the Components are Final Concentrations)
NH4Cl 12.1 g/L KH2PO4 1.5 g/L MgSO4•7H2O 1 g/L Thiamine hydrochloride 0.1 mg/L
FeSO4•7H2O 1.7 mg/L Na2MoO4•2H2O 0.15 mg/L CoCl2•6H2O 0.7 mg/L MnCl•4H2O 1.6 mg/L ZnSO4•7H2O 0.3 mg/L CuSO4•5H2O 0.25 mg/L
Components 3:
Tryptone 0.6 g/L Yeast extract 0.3 g/L NaCl 0.6 g/L
Calcium carbonate 20 g/L
L-Histidine hydrochloride monohydrate 135 mg/L
Sodium thiosulfate 0.6 g/L
Pyridoxine hydrochloride 2 mg/L
For these components, stock solutions were prepared of 10-fold concentration (Components 1), 1000-fold concentration (Components 2), 100/6-fold concentration (Components 3), 100-fold concentration (Component 5), 1750/3-fold concentration (Component 6), 1000-fold concentration (Component 7), and 20-fold concentration (Component 8), they were mixed at the time of use, and the defined volume was obtained with sterilized water to attain the final concentrations. Sterilization was performed by autoclaving at 110° C. for 30 minutes (Components 1, 2, 3, 5 and 8), dry heat sterilization at 180° C. for 5 hours or longer (Component 4), or filter sterilization (Components 6 and 7). The L-cysteine production culture was performed as follows. Each L-cysteine-producing strain was spread on LB agar medium to perform pre-culture overnight at 34° C., and then cells corresponding to about 7 cm on the plate were scraped with an inoculation loop of 10-0 size (NUNC Blue Loop), and inoculated into 2 ml of the L-cysteine production medium contained in a large test tube (internal diameter: 23 mm, length: 20 cm) so as to make cell amounts at the time of the start of the culture substantially the same. Culture was performed at 37° C. with shaking, and terminated when glucose contained in the medium was completely consumed (21 to 24 hours). L-Cysteine produced in the medium was quantified by the method described by Gaitonde, M. K. (Biochem. J., 104(2):627-33, August 1967). In order to allow the strains to harbor the plasmids, chloramphenicol (25 mg/L) was added over the entire culture period. The experiment was performed in quadruplicate for each strain, and averages and standard deviations for the concentrations (g/L) of the accumulated cysteine are shown in Table 1.
It was revealed that, by enhancing expression of the cysG gene coding for the synthetase for siroheme, which is a cofactor of sulfite reductase, and further, by enhancing expression of the cysJI genes coding for the subunits of sulfite reductase in addition to the cysG gene, production of cysteine by fermentation in E. coli using thiosulfate as a sulfur source could be improved.
Table 1: Effect of enhancement of expression of genes involved in sulfite reduction in E. coli cysteine-producing bacterium, MG1655int-4M/pACYC-DES
L-Cysteine Strain (g/L) MG1655int-4M/pACYC-DES/5JS 0.28 ± 0.04 MG1655int-4M/pACYC-DES/pMIV-Pnlp23-cysG (Ec) 0.60 ± 0.01 MG1655int-4M/pACYC-DES/pMIV-Pnlp23-cysGJI (Ec) 0.51 ± 0.05 MG1655int-4M/pACYC-DES/pMIV-Pnlp8-cysG (Pa) 0.57 ± 0.05 MG1655int-4M/pACYC-DES/pMIV-Pnlp23-cysGJI (Pa) 0.58 ± 0.01
SEQ ID NO: 1: Nucleotide sequence of Pnlp0
SEQ ID NO: 2: Nucleotide sequence of Pnlp23
SEQ ID NOS: 3 and 4: Primers for amplification of P. ananatis cysG gene
SEQ ID NOS: 5 and 6: Primers for amplification of P. ananatis cysJI genes
SEQ ID NO: 7: Primer for amplification of P. ananatis cysGJI genes
SEQ ID NOS: 8 and 9: Primers for amplification of E. coli cysG gene
SEQ ID NOS: 10 and 11: Primers for amplification of E. coli cysJI genes
SEQ ID NO: 12: Primer for amplification of E. coli cysGJI genes
SEQ ID NOS: 13 to 20: Primers P1 to P8
SEQ ID NO: 21: Nucleotide sequence of Pnlp8
SEQ ID NOS: 22 and 23: Primers for amplification of E. coli ydeD gene
SEQ ID NOS: 24 to 27: Primers for amplification of cysEX gene
SEQ ID NOS: 28 and 29: Primers for amplification of serA5 gene
SEQ ID NOS: 30 and 31: Primers for amplification of promoter PompA
SEQ ID NOS: 32 and 33: Primers P9 and P10
SEQ ID NO: 34: Nucleotide sequence of Pnlp4
SEQ ID NO: 35: Nucleotide sequence of E. coli cysM gene
SEQ ID NO: 36: Amino acid sequence of E. coli CysM protein
SEQ ID NOS: 37 and 38: Primers P11 and P12
SEQ ID NO: 39: Nucleotide sequence of E. coli cysJ gene
SEQ ID NO: 40: Amino acid sequence of E. coli CysJ protein
SEQ ID NO: 41: Nucleotide sequence of P. ananatis cysJ gene
SEQ ID NO: 42: Amino acid sequence of P. ananatis CysJ protein
SEQ ID NO: 43: Nucleotide sequence of E. coli cysI gene
SEQ ID NO: 44: Amino acid sequence of E. coli CysI protein
SEQ ID NO: 45: Nucleotide sequence of P. ananatis cysI gene
SEQ ID NO: 46: Amino acid sequence of P. ananatis CysI protein
SEQ ID NO: 47: Nucleotide sequence of E. coli cysG gene
SEQ ID NO: 48: Amino acid sequence of E. coli CysG protein
SEQ ID NO: 49: Nucleotide sequence of P. ananatis cysG gene
SEQ ID NO: 50: Amino acid sequence of P. ananatis CysG protein
SEQ ID NO: 51: Nucleotide sequence of Pnlp0 including ligation site for downstream gene
SEQ ID NO: 52: Nucleotide sequence of Pnlp8 including ligation site for downstream gene
1. A method for producing L-cysteine, a related substance thereof, or a mixture thereof, which comprises:
A) culturing a bacterium belonging to the genus Escherichia in a medium comprising thiosulfate, which bacterium has L-cysteine-producing ability and is modified so that expression of a gene involved in sulfite reduction is increased by a method selected from the group consisting of increasing copy number of the gene involved in sulfite reduction, modifying an expression control sequence of the gene, and combinations thereof; and
B) collecting L-cysteine, a related substance thereof, or a mixture thereof from the medium,
wherein the gene involved in sulfite reduction is a cysG gene, and
wherein the cysG gene comprises a DNA selected from the group consisting of:
(a) a DNA comprising the nucleotide sequence of SEQ ID NO: 47 or 49,
(b) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 48 or 50, and
(c) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 48 or 50, but which includes one to 10 amino acid substitutions, deletions, insertions, or additions.
2. The method according to claim 1, wherein the bacterium is further modified so that expression of a cysJ gene and a cysI gene is increased by a method selected from the group consisting of increasing copy number of the cysJ and cysI gene, modifying an expression control sequence of the cysJ and cysI gene, and combinations thereof,
wherein the cysJ gene comprises a DNA selected from the group consisting of:
(d) a DNA comprising the nucleotide sequence of SEQ ID NO: 39 or 41,
(e) a DNA hybridizable with a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 39 or 41 under stringent conditions comprising washing at a salt concentration corresponding to 0.1×SSC, 0.1% SDS at 68° C.,
(f) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 40 or 42, and
(g) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 40 or 42 but which includes one to 10 amino acid substitutions, deletions, insertions, or additions; and
wherein the cysI gene comprises a DNA selected from the group consisting of:
(h) a DNA comprising the nucleotide sequence of SEQ ID NO: 43 or 45,
(i) a DNA hybridizable with a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 43 or 45 under stringent conditions comprising washing at a salt concentration corresponding to 0.1×SSC, 0.1% SDS at 68° C.,
(j) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 44 or 46, and
(k) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 44 or 46 but which includes one to 10 amino acid substitutions, deletions, insertions, or additions.
3. The method according to claim 1, wherein the bacterium is Escherichia coli.
4. The method according to claim 1, wherein the bacterium further has a characteristic selected from the group consisting of:
5. The method according to claim 1, wherein the related substance is L-cystine or a thiazolidine derivative.
5856148 January 5, 1999 Burlingame
5972663 October 26, 1999 Winterhalter et al.
6218168 April 17, 2001 Leinfelder et al.
7759094 July 20, 2010 Rieping
8008048 August 30, 2011 Nonaka et al.
20030077766 April 24, 2003 Takagi et al.
20050009162 January 13, 2005 Maier et al.
20050069994 March 31, 2005 Ptitsyn et al.
20050112731 May 26, 2005 Kashiwagi et al.
20050124049 June 9, 2005 Ziyatdinov et al.
20050221453 October 6, 2005 Takagi et al.
20070026505 February 1, 2007 Madden et al.
20080076163 March 27, 2008 Takagi et al.
20090226984 September 10, 2009 Nonaka et al.
20090298136 December 3, 2009 Zelder et al.
20100047879 February 25, 2010 Figge et al.
20100209977 August 19, 2010 Takumi et al.
20100216196 August 26, 2010 Nonaka et al.
20100233765 September 16, 2010 Nonaka et al.
20110033902 February 10, 2011 Nonaka et al.
20110177566 July 21, 2011 Savrasova et al.
20110212496 September 1, 2011 Takikawa et al.
20120190084 July 26, 2012 Schneider et al.
2386539 Al April 2001 CA
2386539 April 2007 CA
2479279 July 2012 EP
11-155571 June 1999 JP
2002-233384 August 2002 JP
2003-511086 March 2003 JP
2003-169668 June 2003 JP
2005-245311 September 2005 JP
2005-287333 October 2005 JP
2009-501550 January 2009 JP
2010-022215 February 2010 JP
WO03/006666 January 2003 WO
WO2005/108561 November 2005 WO
WO2006/082254 August 2006 WO
WO2007/077041 July 2007 WO
WO2008/127240 October 2008 WO
WO2009/043372 April 2009 WO
Stoupe et al., Sulfite reductase hemoprotein in Handbook of Metalloproteins (Messerschmidt et al., eds.), 2001, 471-485.
Kredich, The molecular basis for positive regulation of cys promoters in Salmonella typhimurium and Escherichia coli, Mol. Microbiol., 1992, 6, 2747-53.
Chambers et al., Cysteine and S-sulphocysteine biosynthesis in bacteria, Arch. Mikrobiol., 1971, 77, 165-84.
Wu et al., High-level expression of Escherichia coli NADPH-sulfite reductase: requirement for a cloned cysG plasmid to overcome limiting siroheme cofactor, J. Bacteriol., 1991, 173, 325-33.
Ostrowski et al., Characterization of the cysJIH Regions of Salmonella tryphimurium and Escherichia coli B, J. Biol. Chem., 1989, 264, 15726-37.
Ostrowski et al., Characterization of the flavoprotein moieties of NADPH-sulfite reductase from Salmonella typhimurium and Escherichia coli, J. Biol. Chem., 1989, 264, 15796-15808.
Wahl et al., Molecular hybridization of immobilized nucleic acids, Methods Enz., 1987, 152, 399-407.
Kredich, Biosynthesis of Cysteine in Escherichia coli and Salmonella Cellular and Molecular Biology, Neidhardt, F.C., Ed., 2nd Edition, vol. 1, ASM Press, 1996, pp. 514-527.
International Search Report for PCT Patent App. No. PCT/JP2012/058696 (Jul. 3, 2012).
Supplementary European Search Report for European Patent App. No. 12767953.8 (Nov. 24, 2014).
Warren, M. J., et al., “The Escherichia coil cysG gene encodes 5-adenosylnnethione-dependent uroporphyrinogen III methylase,” Biochem. J. 1990;265:725-729.
Dassler, T., et al., “Identification of a major facilitator protein from Escherichia coli involved in efflux of metabolites of the cysteine pathway,” Mol. Microbiol. 2000;36(5):1101-1112.
Eschenbrenner, M., et al., “The Flavin Reductase Activity of the Flavoprotein Component of Sulfite Reductase from Escherichia coli,” J. Biol. Chem. 1995;270(35):20550-20555.
Gaudu, P., et al., “The NADPH:sulfite reductase of Escherichia coli is paraquat reductase,” Eur. J. Biochem. 1994;226:459-463.
Li, C., et al., “Cloning of the 3′-phosphoadenylyl sulfate reductase and sulfite reductase genes and Escherichia coli K-12,” Gene 1987;53:227-234.
MacDonald, H., et al., “Molecular cloning and functional analysis of the cysG and nirB genes of Escherichia coli K12, two closely-linked genes required for NADH-dependent nitrite reductase activity,” Mol. Gen. Genet. 1985;200:328-334.
Peakman, T., et al., “Nucleotide sequence, organisation and structural analysis of the products of genes in the nirB-cysG region of the Escherichia coli K-12 chromosome,” Eur. J. Biochem. 1990;191:315-323.
Spencer, J. B., et al., “The Escherichia coli cysG gene encodes the multifunctional protein, siroheme synthase,” FEBS Lett. 1993;335(1):57-60.
Patent number: 9234223
Patent Publication Number: 20120252076
Inventors: Shunsuke Yamazaki (Kawasaki), Gen Nonaka (Kawasaki), Kazuhiro Takumi (Kawasaki)
Primary Examiner: Robert Mondesi
Assistant Examiner: Todd M Epstein
Application Number: 13/431,104
Current U.S. Class: Methionine; Cysteine; Cystine (435/113)
International Classification: C12P 13/12 (20060101); C12N 9/02 (20060101); C12N 9/10 (20060101); C12N 9/88 (20060101);